Data gathered: December 23
Alternative Data for Clene
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 95 | Sign up | Sign up | Sign up |
| Webpage traffic | 3,000 | Sign up | Sign up | Sign up |
| Google Trends | 36 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 28 | Sign up | Sign up | Sign up |
| Facebook Followers | 307 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 8 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 3,105 | Sign up | Sign up | Sign up |
| Twitter Followers | 821 | Sign up | Sign up | Sign up |
| Twitter Mentions | 7 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Lobbying Cost | $67,000 | Sign up | Sign up | Sign up |
| Linkedin Employees | 66 | Sign up | Sign up | Sign up |
About Clene
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics.
| Price | $4.72 |
| Target Price | Sign up |
| Volume | 39,330 |
| Market Cap | $35M |
| Year Range | $3.88 - $8.74 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Drug Manufacturers |
In the news
 |
Clene Inc. Enters Into Note Purchase Agreement with Initiation of Clene Senior Secured Convertible Promissory NotesOn December 17, 2024, Clene Inc. (NASDAQ: CLNN) announced the commencement of a note purchase agreement (the “Note Purchase Agreement”)December 22 - ETF Daily News |
 |
Clene secures debt facility to pay off existing senior loanDecember 19 - Thefly.com |
 |
IBN Coverage: Clene (NASDAQ: CLNN) Secures $10M Debt Facility to Advance Neurodegenerative Disease TreatmentsDecember 19 - Yahoo |
 |
Clene Improves Cash Position and Runway by Securing New Debt Facility to Pay Off Existing Senior LoanDecember 18 - Yahoo |
 |
Clene (NASDAQ:CLNN) Given “Buy” Rating at D. Boral CapitalDecember 11 - ETF Daily News |
 |
IBN Coverage: Clene (NASDAQ: CLNN) Advances CNM-Au8 in ALS With FDA Guidance on Accelerated Approval PathwayDecember 11 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 87,000 | 18,000 | 69,000 | -8M | -7.6M | -1.107 |
| Q2 '24 | 91,000 | 18,000 | 73,000 | -6.8M | -7.2M | -1.060 |
| Q1 '24 | 73,000 | 16,000 | 57,000 | -11M | -9.8M | -0.090 |
| Q4 '23 | 170,000 | 38,000 | 130,000 | -10M | -8.9M | -0.060 |
| Q3 '23 | 110,000 | 12,000 | 96,000 | -2.4M | -1.2M | -0.020 |
Insider Transactions View All
| Etherington Robert Dee filed to buy 40,149 shares at $4.8. October 1 '24 |
| Mortenson Mark filed to buy 28,949 shares at $4.8. October 1 '24 |
| MATLIN DAVID J filed to buy 444,491 shares at $4.8. October 2 '24 |
| General Resonance LLC filed to sell 15,313,712 shares at $0.4. May 8 '24 |
| General Resonance LLC filed to sell 15,349,712 shares at $0.3. May 1 '24 |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$145.27 0.6% | 40 |
 |
Eli Lilly and CompanyLLY |
$796.28 3.7% | 60 |
 |
PfizerPFE |
$26.71 1.3% | 39 |
 |
AstrazenecaAZN |
$66.63 2% | 55 |
 |
AbbVieABBV |
$178.39 1.6% | 60 |
Read more about Clene (CLNN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, lobbying cost & linkedin employees.
What is the Market Cap of Clene?
The Market Cap of Clene is $35M.
What is the current stock price of Clene?
Currently, the price of one share of Clene stock is $4.72.
How can I analyze the CLNN stock price chart for investment decisions?
The CLNN stock price chart above provides a comprehensive visual representation of Clene's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Clene shares. Our platform offers an up-to-date CLNN stock price chart, along with technical data analysis and alternative data insights.
Does CLNN offer dividends to its shareholders?
As of our latest update, Clene (CLNN) does not offer dividends to its shareholders. Investors interested in Clene should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Clene?
Some of the similar stocks of Clene are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
.